February 27, 2017
Premaitha Health buys Taiwanese Yourgene Bioscience
Premaitha Health, an international molecular diagnostics group focused on prenatal testing, has acquired Taiwanese Yourgene Bioscience.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
February 27, 2017
Midatech borrows £6 million
Midatech has borrowed £6 million from Silicn Valley Bank to add to the placing of the shares it made in October last year.
February 27, 2017
Sanofi teams up with Lonza to invest €270 million in a mammalian cell culture site in Switzerland
Sanofi and Lonza will invest €270 million (CHF 290 million) in a mammalian cell culture site for monoclonal antibody production in Swiss town of Visp, planned for opening in 2020.
February 27, 2017
CTI BioPharma appoints hematology specialist as CEO
CTI BioPharma has appointed Adam Craig, M.D., Ph.D., as President and Chief Executive Officer (CEO) and member of the Board of Directors
February 27, 2017
Global Market Insights says clinical trial management system market worth $2 billion by 2024
Growing prevalence of chronic diseases, surge in clinical trials outsourcing, rising R&D cost and favorable government initiatives will drive global clinical trial management system market size, according to a report by Global Market Insights.
February 24, 2017
Novartis makes first step in making Tafinlar + Mekinist available for certain NSCLC patients
Novartis could get first targeted treatment for patients with BRAF non-small cell lung cancer if European Medicines Agency (EMA) approves Tafinlar+Mikinist combination.
February 24, 2017
Oncology focused drugmaker Xynomic Pharmaceuticals secures Abexinostat global rights
Oncology drug research and development company Xynomic Pharmaceuticals has acquired exclusive worldwide rights to develop a novel HDAC inhibitor targeting hematological and solid tumors, Abexinostat.
February 24, 2017
Galapagos starts Phase 1 study for cystic fibrosis drug, reports net profit of €54M for 2016
Galapagos has started dosing the first healthy volunteer with a combination of novel corrector GLPG2222 and novel potentiator GLPG2451 for cystic fibrosis in a Phase 1 study.
February 24, 2017
OncoGenex has enough money for next year as it waits a mid-year merger with Achieve Life Sciences
Vancouver-based drugmaker OncoGenex didn’t make any revenues in the fourth quarter 2016, and it finished the year with a net loss for the fourth quarter and year ended December 31, 2016 of $5.8 million and $20.1 million, respectively.
February 24, 2017
Oxford BioMedica reports positive results for advanced colorectal cancer drug
Oxford BioMedica, a gene and cell therapy group, has presented results from a Phase I/II clinical trial of MVA-5T4 immunotherapy (TroVax) and low dose cyclophosphamide (CPM) in patients with advanced colorectal cancer (TaCTiCC).